Rolke James 4
4 · LA JOLLA PHARMACEUTICAL CO · Filed May 19, 2020
Insider Transaction Report
Form 4
Rolke James
Chief Scientific Officer
Transactions
- Award
Common Stock
2020-05-15$5.86/sh+140$820→ 81,566 total - Award
Stock Option (Right to Buy)
2020-05-15+140→ 140 totalExercise: $6.89Exp: 2030-05-15→ Common Stock (140 underlying)
Footnotes (2)
- [F1]These shares were acquired on 05/15/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- [F2]The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.